Compare Amphastar Pharmaceuticals Inc (AMPH) vs SpaceX (SPCX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

SPCX trades at $145.44, down 4.42% today, with neutral technical signals and mixed fundamentals. The company reported Q1 2026 EPS of -$1.10, missing expectations, while revenue grew to $18.67B in 2025. Despite negative profitability metrics, analyst consensus remains bullish with a $239.67 price target. Recent Nasdaq-100 inclusion and Starmind AI project announcements highlight growth potential amid significant cash burn from heavy investing activities.

SPCX presents high-risk, high-reward potential with ambitious AI and space infrastructure projects driving long-term optimism. However, negative margins, rich valuations, and upcoming share unlocks pose substantial downside risks. The stock's future hinges on successful execution of Starlink monetization and AI data center initiatives against intense competition and capital intensity.